This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.
Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -18.82% and 8.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More
by Urmimala Biswas
Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.
Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Bio-Rad (BIO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad (BIO) stock based on the movements in the options market lately.
ResMed (RMD) Stock Jumps 3.8%: Will It Continue to Soar?
by Zacks Equity Research
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Sell Stocks for September 19th
by Zacks Equity Research
BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.
New Strong Sell Stocks for August 18th
by Zacks Equity Research
BIO, REFI and GPK have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2023.
New Strong Sell Stocks for August 9th
by Zacks Equity Research
BWA, ARR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2023.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.
Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 17.65% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 213.04% and 96.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.
Are Options Traders Betting on a Big Move in Bio-Rad Laboratories (BIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.
Bio-Rad Laboratories (BIO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $377.68, marking a +0.09% move from the previous day.
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $364.38 in the latest trading session, marking a -0.37% move from the prior day.
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day.
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed the most recent trading day at $376.56, moving -0.66% from the previous trading session.
Bio-Rad Laboratories (BIO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $361.03, marking a +0.43% move from the previous day.
Perrigo (PRGO) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $372.36, marking a +0.27% move from the previous day.
Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
by Zacks Equity Research
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?